Rezolute reported a narrowed net loss of $20.5 million for the fourth quarter ended June 30, 2026, as the company focused on late-stage clinical development for its lead candidate, ersodetug. The company maintains a liquidity position of $107.8 million to support its ongoing Phase 3 programs.
Key Highlights
- Interim Phase 3 upLIFT data for tumor hyperinsulinism showed 7 of 8 participants met the primary responder criterion, with results expected by year-end 2026.
- Cash, cash equivalents, and marketable securities totaled $107.8 million, a decrease from $167.9 million at the end of fiscal 2025.
- Fourth quarter research and development expenses declined to $14.9 million from $20.9 million year-over-year, primarily due to lower manufacturing costs for ersodetug.